|
ERF expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.080970E-01 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.644240E-01 |
| Normal-vs-Stage2 |
8.835700E-02 |
| Normal-vs-Stage3 |
4.174400E-02 |
| Normal-vs-Stage4 |
2.794000E-01 |
| Stage1-vs-Stage2 |
4.420400E-01 |
| Stage1-vs-Stage3 |
1.375780E-01 |
| Stage1-vs-Stage4 |
7.562400E-01 |
| Stage2-vs-Stage3 |
7.519600E-01 |
| Stage2-vs-Stage4 |
3.461600E-01 |
| Stage3-vs-Stage4 |
1.863040E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.299800E-01 |
| Normal-vs-AfricanAmerican |
8.591800E-01 |
| Normal-vs-Asian |
3.778600E-01 |
| Caucasian-vs-AfricanAmerican |
1.920780E-01 |
| Caucasian-vs-Asian |
4.517800E-01 |
| AfricanAmerican-vs-Asian |
4.652000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.895410E-01 |
| Normal-vs-Female |
9.380300E-02 |
| Male-vs-Female |
5.079800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.433800E-01 |
| Normal-vs-Age(41-60Yrs) |
7.835800E-02 |
| Normal-vs-Age(61-80Yrs) |
2.266200E-02 |
| Normal-vs-Age(81-100Yrs) |
7.735800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.134600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.872190E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.504600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.666000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.238400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.354600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.70942999999646E-05 |
| Classical-VS-Follicular |
9.122300E-03 |
| Classical-VS-Other |
9.651600E-01 |
| Classical-VS-Normal |
3.137600E-01 |
| Tall-VS-Follicular |
7.974000E-02 |
| Tall-VS-Other |
3.045900E-02 |
| Tall-VS-Normal |
1.077160E-03 |
| Follicular-VS-Other |
4.418400E-01 |
| Follicular-VS-Normal |
2.845500E-02 |
| Other-VS-Normal |
4.892800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.108500E-02 |
| Normal-vs-N1 |
4.672200E-01 |
| N0-vs-N1 |
2.930300E-02 |
|
|
